By Michal Yoshai-Horovits
Globes, Jan. 22, 2007

Eli Lilly & Co. will support Phase II clinical trials by Bio-Light Life Sciences Investments, Ltd, portfolio company Obecure Ltd.
The trial of Obecure's OBE101 drug will be conducted in Canada on 78 schizophrenia patients taking Eli Lilly's anti-psychotic drug Zyprexa.
Eli Lilly's support for the trial could total a few hundred thousand dollars. Obecure will allow Eli Lilly to review the results of the trial before publication.
The trial will examine the effectiveness of OBE101, compared with a placebo in preventing weight gain as a side effect of taking Zyprexa.